Why an intermediate strength exists

The UK schedule allows increases of 2.5 mg after at least four weeks on the current dose, when you need an increase. Moving through an in-between strength makes the change gradual. At 7.5 mg you take the same medicine, working in the same way.

The product information names 5, 10 and 15 mg as the adult maintenance strengths. If your prescriber suggests staying on 7.5 mg for longer, ask how that plan fits your situation. The label's list is no instruction to push on while you feel unwell.

No reliable weight-loss figure exists for 7.5 mg

The main fixed-dose groups in SURMOUNT-1 took 5, 10 and 15 mg. Nobody can work out your 7.5 mg result by taking the midpoint of two trial percentages. Your time on treatment, the weight you have already lost and your own health all affect the outcome.

Comparing your first weeks at 7.5 mg with someone who started at a different weight tells you little about your next dose. Compare your progress with the treatment goals you agreed with your prescriber. Judge it over a suitable period and weigh it against any side effects.

What to watch after moving up

Digestive symptoms sometimes start or get stronger after an increase. Note whether nausea, fullness, reflux or bowel changes are mild and easing, or whether they stop you drinking and eating properly. A familiar symptom may still need attention if it has become more severe.

Get urgent medical assessment for severe, persistent abdominal pain. An online discussion about dose changes is the wrong place for it. If pancreatitis is suspected, do not take further doses while doctors investigate. Being unable to keep fluids down, feeling faint or passing less urine also need prompt clinical advice.

Get more from your review

Bring a short record of injection dates, your weight trend, symptoms and how they affect daily life. If you have diabetes, bring the glucose readings your clinician asked for. List any changes to other medicines, including products bought without a prescription, because they may add to constipation, nausea or dizziness.

Ask your prescriber directly what benefit the change in strength should bring. That leads to a better conversation than asking whether the next pen is in stock. Better glucose control, easier movement or fewer weight-related symptoms all count, even when the scales move slowly.

Never improvise a dose

Do not split a stronger pen or draw out leftover liquid to make a 7.5 mg dose. Each prescribed KwikPen and its instructions deliver one set dose. A maths conversion cannot make a modified technique safe, and changing the amount makes your clinical record unreliable.

If a supply delay or cost problem looks likely to interrupt treatment, tell your prescriber early. A planned alternative is safer than stretching the gap between doses on your own or buying a different strength from an unverified seller. Any restart should take account of the length of the gap and the symptoms you had before.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Mounjaro UK Summary of Product Characteristics, updated September 2026 medicines.org.uk
  2. Mounjaro UK patient information leaflet medicines.org.uk
  3. SURMOUNT-1: tirzepatide once weekly for obesity pubmed.ncbi.nlm.nih.gov
  4. NICE: prescribing, reviewing and stopping tirzepatide nice.org.uk

Spotted something out of date? Report a mistake.